TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01198860
Drug: CTH Chronic Hepatitis B
Normalized name: HEPATITIS B
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug:~* Tenofovir/ 300mg daily~* Phyllanthus Urinaria/300mg daily~* Adenosma Glutinosum/150mg daily~* Eclipta Prostrata/150mg daily~* Ascorbic Acid / 500mg daily
Study: NCT04906109
Drug: Vemlidy Tab
Normalized name: Vemlidy
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1T
Study: NCT04906109
Drug: DA-2803 Tab
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1T
Study: NCT03399838
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IN Dex for pediatric procedural sedation at the emergency department
Study: NCT03399838
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: po/pr midazolam as active comparator to dexmedetomidine for pediatric procedural sedation at the pediatric emergency department
Study: NCT06485739
Drug: Irinotecan liposomes combined with cisplatin/carboplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irinotecan liposomes 70mg/m2，use on the first day of each cycle The dosage of cisplatin and carboplatin is determined by the researchers
Study: NCT02844530
Drug: 90Y-epratuzumab tetraxetan
Normalized name: TETRAXETAN
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Primary objective is to compare the complete response rate (CR + CRp) after 2 injections of 370 MBq/m² of 90Y-epratuzumab tetraxetan RIT at day 1 and day 8 versus standard of care salvage chemotherapy regimens in adult CD22+ relapsed/refractory B-ALL.~A second RIT cycle (consolidation) will be allowed in the experimental group in case of response (CR or CRp).~From an ethical point of view, it will be also permitted to propose the RIT experimental treatment in the control group in case of treatment failure or relapse during the 6 months following inclusion. Follow-up will be also 12 months from the RIT for these patients
Study: NCT05785065
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The participant will receive 500 mg to 1000 mg twice daily of mycophenolate mofetil administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day
Study: NCT04658303
Drug: Pimonidazole
Normalized name: Pimonidazole
DrugBank: Pimonidazole (DB12485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimonidazole is not used with therapeutic intent, and has a non-hazardous designation. It has been widely used for in-vivo evaluation of intratumor hypoxia, and patients will take PO pimonidazole before the scheduled biopsy. Patients receive an oral dose of pimonidazole, a safe chemical tracer up to 24 hours prior to biopsy. Pimonidazole allows for true hypoxia staining; pimonidazole binds hypoxic proteins covalently, creating an antigen that facilitates the imaging, flow cytometry, and scRNA-seq experiments proposed. Pimonidazole has been previously used in patients and is safe and well tolerated, without anticipated adverse events.
Study: NCT03825536
Drug: Oral Methamphetamine
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this phase IV double-blind randomized crossover study, participants will be randomized to either of two treatment arms, oral methamphetamine or placebo, using a crossover design with a 31-day washout period in between treatment arms. For the oral methamphetamine treatment arm, an initial 10 mg of oral methamphetamine (over-encapsulated to look similar to placebo capsule) study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose (over-encapsulated to look similar to placebo capsule) two hours later.
Study: NCT01298882
Drug: Diacerein
Normalized name: diacerein
DrugBank: Diacerein (DB11994)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04930107
Drug: Fluconazole 150 mg
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment will be offered to participants if clinical exam and clinical samples are consistent with vulvovaginal candidiasis (VVC). Females presenting with a suspected first-time yeast infection will be treated with fluconazole 150 mg orally.
Study: NCT04930107
Drug: Boric Acid Supp,Vag
Normalized name: BORIC ACID SUPP,VAG
DrugBank: Boric acid (DB11326)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment will be offered to participants if clinical exam and clinical samples are consistent with vulvovaginal candidiasis (VVC). Women that have had a prior documented VVC infection that has recurred on fluconazole will be treated with boric acid, 600 mg intravaginally at bedtime for 7 days.
Study: NCT05834868
Drug: Insulin Lispro Injection
Normalized name: Insulin Lispro Injection
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug:Insulin Lispro Injection Injected subcutaneously three times a day. Dose was individually adjusted.
Study: NCT05484583
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance phase (administered every 4 weeks): Durvalumab intravenous infusion
Study: NCT05302297
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical Form: Concentrate solution for injection for intravenous (IV) infusion Route of Administration: Intravenous (IV) infusion
Study: NCT05515783
Drug: 68Ga-FAP-RGD
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose will be 4-7mCi given intravenously.
Study: NCT05515783
Drug: 68Ga-FAP-RGD
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) given intravenously at a single time prior to imaging. 68Ga-FAPI-02, the dose will be 1.8 (MBq /kg) given intravenously at a single time prior to imaging; 18F-FDG, the dose will be 3.7 (MBq / kg) given intravenously at a single time prior to imaging.
Study: NCT05351489
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive intrathecal 2 mL heavy bupivacaine 0. 5% together with either dexmedetomidine 5 μg or10 μg dexmedetomidine .
Study: NCT06016270
Drug: hSTC810 400 mg + Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: hSTC810 400 mg and paclitaxel 175 mg/m2 will be administered as an intravenous (IV) infusion~Paclitaxel: 175 mg/m2 will be administered as an IV infusion
Study: NCT06016270
Drug: hSTC810 800 mg + Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: hSTC810 800 mg and paclitaxel 175 mg/m2 will be administered as an IV infusion
Study: NCT06344169
Drug: Sebacoyl Dinalbuphine Ester
Normalized name: lutein esters
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SDE will be dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance
Study: NCT06344169
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of morphine (0.15mg) will be administered along with bupivacaine during spinal anesthesia.
Study: NCT05304715
Drug: Bezlotoxumab
Normalized name: Bezlotoxumab
DrugBank: Bezlotoxumab (DB13140)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single intravenous infusion of bezlotoxumab
Study: NCT05304715
Drug: Normal saline 0.9% or 5% dextrose water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion - Placebo arm
Study: NCT06385002
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After tracheal intubation, the experimental group will maintain oxygen-air (O2-Air) at 2 liters/minute, and remimazolam will be infused at 1.0mg/kg/h, while adjusting the concentration of sevoflurane to maintain the depth of anesthesia with a bispectral index (BIS) of 40-60.
Study: NCT04706741
Drug: Izokibep
Normalized name: Izokibep
DrugBank: Izokibep (DB19081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Izokibep is an Interleukin-17 Inhibitor that will be administered subcutaneously
Study: NCT04706741
Drug: Prednisone/Prednisolone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Background Corticosteroid
Study: NCT05565274
Drug: Pentazocine plus placebo
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg of pentazocine and 2milliLitre of injection water
Study: NCT04680637
Drug: Efavaleukin Alfa
Normalized name: Efavaleukin alfa
DrugBank: Efavaleukin alfa (DB16149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a subcutaneous (SC) injection.
Study: NCT05653973
Drug: Endothelin-1
Normalized name: Endothelin-1
DrugBank: Endothelin-1 (DB12652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: endothelin-1, endothelin-1 + BQ-788 (endothelin receptor type B-inhibitor), and endothelin-1 + BQ-123 (endothelin receptor type A-inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelin-mediated constriction and the role of the receptor subtypes in this response.
Study: NCT01561092
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 or 10 mg escitalopram tablets administered orally once daily
Study: NCT05157841
Drug: Bupivacaine liposome injectable suspension 266 mg
Normalized name: bupivacaine liposome Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sciatic nerve block in the popliteal fossa with EXPAREL 266 mg
Study: NCT05157841
Drug: Bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sciatic nerve block in the popliteal fossa with Bupivacaine HCl
Study: NCT05157841
Drug: Bupivacaine liposome injectable suspension 133 mg
Normalized name: bupivacaine liposome Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sciatic nerve block in the popliteal fossa with EXPAREL 133 mg
Study: NCT04844918
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06110065
Drug: CT-guided Pudendal Nerve Cryoneurolysis
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided bilateral pudendal nerve cryoneurolysis involves using advanced imaging technology to precisely target and freeze the pudendal nerves, which are responsible for transmitting pain signals.
Study: NCT05284019
Drug: Eptinezumab
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Concentrate for solution for IV infusion
Study: NCT05284019
Drug: Erenumab
Normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution for SC Injection
Study: NCT05284019
Drug: Onabotulinumtoxin-A
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Solution for IM Injection
Study: NCT05284019
Drug: Fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution for SC Injection
Study: NCT05284019
Drug: Galcanezumab
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution for SC Injection
Study: NCT05713760
Drug: Tirbanibulin Ointment 1%
DrugBank: Tirbanibulin (DB06137)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Klisyri® ointment is a microtubule inhibitor for topical use and is currently on the market for the treatment of actinic keratosis of the face or scalp. The chemical name of tirbanibulin is N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl) acetamide. Tirbanibulin ointment 1% contains 10 mg tirbanibulin per gram of white to off-white ointment containing mono- and di-glycerides and propylene glycol and is supplied in packets containing 250 mg of tirbanibulin ointment 1%. Each packet includes single-dose packets (2.5 mg tirbanibulin in 250 mg) to be applied to evenly cover up to 25 cm² of the treatment field once daily for 5 consecutive days using 1 single-dose packet per application.
Study: NCT05437822
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 g of tranexamic acid in 50 mL of saline
Study: NCT06490601
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide glutarimide is derivation of glutamic acid. Potentiating of fetal hemoglobin expression occurs by up regulation of Erythroid transcription factor and Erythroid Krüppel-like factor expression Furthermore few studies also concluded that thalidomide hypomethylate 27th amino acid in Histone H3 in the gamma globin gene. Initiating cause of this process is suppression of Nuclear factor (kappa-light-chain-enhancer of activated B cells) activation by tumor necrosis factor -alpha , Vascular endothelial growth factor , Prostaglandin E2 and inflammatory cytokine.~Investigating the impact of thalidomide on transfusion-dependent beta thalassemia patients is essential for discerning its therapeutic efficacy and safety profile.
Study: NCT05291221
Drug: intratracheal Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At the end of the operation by 15min, Dexmedetomidine (0.5µg/kg, diluted in 5mL saline in a medical spray bottle) was sprayed down the intratracheal tube of patients
Study: NCT05291221
Drug: intratracheal Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At the end of the operation by 15min, (5ml) 2% of lidocaine was sprayed down the intratracheal tube of patients.
Study: NCT01025934
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04845035
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: By mouth
Study: NCT04845035
Drug: Ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: By mouth
Study: NCT05112211
Drug: Doxycycline Hyclate
Normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients administrated with doxycycline tablets 100mg orally per day
Study: NCT04979247
Drug: Oliceridine
Normalized name: Oliceridine
DrugBank: Oliceridine (DB14881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Near the end of surgery, patients will be given ≤1.5 mg of oliceridine as a bolus. Postoperatively, patient-controlled analgesia (PCA) will be started with no background infusion, demand doses of 0.35 mg, with a 6 minute lock-out. Additional boluses (≤1 mg) of oliceridine will be given as deemed necessary (based on NRS score and clinical assessment of the patient) as soon as 15 minutes after the initial 1.5 mg loading dose. In addition to supplemental 1 mg bolus doses, the PCA demand dose can be increased to a maximum of 0.5 mg oliceridine.
Study: NCT05341375
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Group TE received s-ketamine anesthesia induction dose of 0.3 mg/kg on the basis of TA group. Anesthesia maintenance dose of 0.2ug/kg/h was pumped to 30min before the end of the operation
Study: NCT06486142
Drug: Afatinib/Dacomitinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Second-generation EGFR-inhibitors
Study: NCT06486142
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Third-generation EGFR-inhibitor
Study: NCT06251999
Drug: fospropofol sedation
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fospropofol sedation for same-day bidirectional endoscopy in elderly patients
Study: NCT06251999
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol
Study: NCT05097768
Drug: Dexamethasone 0.5mg
Normalized name: DEXAMETHASONE 0.5MG TAB
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients will be randomly given the medication by mouth 60 min before administering IANB.
Study: NCT05241132
Drug: Tislelizumab plus chemotherapy
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Cisplatin: 100mg/m2, injected intravenously every 3 weeks, 8 cycles (period 21 days)~2. Paclitaxel (albumin-bound) : paclitaxel, 175mg/m2, given intravenously every 3 weeks for 8 cycles (period 21 days).~3. Tislelizumab: 200mg, given intravenously every 3 weeks until disease progression or unacceptable toxicity or death or subject withdrawal of informed consent.
Study: NCT04582305
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional bleomycin treatment administered with an electronic pneumatic jet injector
Study: NCT05754684
Drug: Dinutuximab beta
Normalized name: dinutuximab beta
DrugBank: Dinutuximab (DB09077)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dinutuximab beta iv for 5 days
Study: NCT05754684
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 sc alternate day for 6 doses
Study: NCT05754684
Drug: Granulocyte-Macrophage Colony-Stimulating Factor
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony-stimulating factor sc daily till ANC \>2,000/mm3
Study: NCT05754684
Drug: Naxitamab
Normalized name: Naxitamab
DrugBank: Naxitamab (DB15965)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naxitamab iv for 4 days (as alternative for dinutuximab)
Study: NCT06493136
Drug: lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: questionnaire
Study: NCT04849377
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 9.0
Study: NCT04849377
Drug: Cisplatin 200
Normalized name: CISPLATIN 200MG/VIL (PF) INJ
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg/m2
Study: NCT04849377
Drug: Cisplatin 240
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 240mg/m2
Study: NCT05309460
Drug: Labetalol Oral Tablet
Normalized name: labetalol Oral Tablet
DrugBank: Labetalol (DB00598)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Labetalol arm.
Study: NCT05309460
Drug: NIFEdipine ER
Normalized name: NIFEdipine ER
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Nifedipine arm.
Study: NCT05531890
Drug: GTX-102 medium dose fast Period 1 and Period 2
Normalized name: Fast Freeze
DrugBank: GTX-102 (DB16981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 fast
Study: NCT05531890
Drug: GTX-102 medium dose slow Period 1 and Period 2
Normalized name: Slow-Fe
DrugBank: GTX-102 (DB16981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 slow
Study: NCT05531890
Drug: GTX-102 high dose fast Period 1 and Period 2
Normalized name: Fast Freeze
DrugBank: GTX-102 (DB16981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered in Period 1 and Period 2 fast
Study: NCT05531890
Drug: GTX-102 low dose fast Period 1 and Period 2
Normalized name: GTX-102
DrugBank: GTX-102 (DB16981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTX-102 Betamethasone oral spray high dose (0.025 mg/kg) administered in Period 1 and Period 2 fast
Study: NCT05531890
Drug: Betamethasone solution as intramuscular injection Period 1 and Period 2
Normalized name: betamethasone Injectable Solution
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: reference product 0.1 mg/kg betamethasone solution as an intramuscular injection
Study: NCT05531890
Drug: Betamethasone Oral Solution Period 1 and Period 2
Normalized name: Betamethasone Oral Solution
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparator product 0.1 mg/kg betamethasone oral drops solution
Study: NCT05727943
Drug: Clioquinol
Normalized name: Clioquinol
DrugBank: Clioquinol (DB04815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: add on clioquinol to concomitant ASM
Study: NCT05815901
Drug: Epaminurad 6 mg
Normalized name: Epaminurad
DrugBank: Epaminurad (DB18973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epaminurad 6 mg tablet
Study: NCT05815901
Drug: Epaminurad 9 mg
Normalized name: Epaminurad
DrugBank: Epaminurad (DB18973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epaminurad 9 mg tablet
Study: NCT05675319
Drug: Allogeneic Stem Cells
Normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic Stem Cell Transplantation
Study: NCT05675319
Drug: carfilzomib/lenalidomide/dexamethasone (KRD)
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: triple regimen for first relapse should be applied according to latest Summary of Product Characteristics (SmPC) version
Study: NCT05675319
Drug: elotuzumab/lenalidomide/dexamethasone (ERD)
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: triple regimen for first relapse should be applied according to latest SmPC version
Study: NCT05675319
Drug: daratumumab/bortezomib/dexamethasone (DVD)
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: triple regimen for first relapse should be applied according to latest SmPC version
Study: NCT05675319
Drug: daratumumab/lenalidomide/dexamethasone (DRD)
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: triple regimen for first relapse should be applied according to latest SmPC version
Study: NCT05675319
Drug: ixazomib/lenalidomide/dexamethasone (IRD)
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: triple regimen for first relapse should be applied according to latest SmPC version